735241-98-2

Basic information

• Product Name: 4-(Chloromethyl)-1-methyl-1H-pyrazole hydrochloride
• Synonyms: 4-(Chloromethyl)-1-methyl-1H-pyrazole hydrochloride;4-(Chloromethyl)-1-methylpyrazole
• CAS NO: 735241-98-2
• Molecular Formula: C₅H₇ClN₂
• Molecular Weight: 167.03642
• Mol File: 735241-98-2.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(Chloromethyl)-1-methyl-1H-pyrazole hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Chloromethyl)-1-methyl-1H-pyrazole hydrochloride(735241-98-2)
• EPA Substance Registry System: 4-(Chloromethyl)-1-methyl-1H-pyrazole hydrochloride(735241-98-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 735241-98-2(Hazardous Substances Data)

Upstream product

• 85290-80-8 ethyl 1-methylpyrazole-4-carboxylate 
• 25016-11-9 1-methylpyrazole-4-carbaldehyde 
• 112029-98-8 (1-methyl-1H-pyrazol-4-yl)-methanol 

Downstream Products

• 754159-15-4 (1-methyl-1H-pyrazol-4-yl)acetonitrile 
• 760951-49-3 4-[(ethylthio)methyl]-1-methyl-1H-pyrazole 
• 1381791-44-1 C₂₄H₁₉ClF₃N₃O₃ 
• 1381791-45-2 2-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}-5-[({1-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-oxo-1,2-dihydro-4-pyridinyl}oxy)methyl]benzonitrile 

Relevant articles and documents

Structure-guided optimization of 1H-imidazole-2-carboxylic acid derivatives affording potent VIM-Type metallo-β-lactamase inhibitors

Production of metallo-β-lactamases (MBLs) in bacterial pathogens is an important cause of resistance to the ‘last-resort’ carbapenem antibiotics. Development of effective MBL inhibitors to reverse carbapenem resistance in Gram-negative bacteria is still needed. We herein report X-ray structure-guided optimization of 1H-imidazole-2-carboxylic acid (ICA) derivatives by considering how to engage with the active-site flexible loops and improve penetration into Gram-negative bacteria. Structure-activity relationship studies revealed the importance of appropriate substituents at ICA 1-position to achieve potent inhibition to class B1 MBLs, particularly the Verona Integron-encoded MBLs (VIMs), mainly by involving ingenious interactions with the flexible active site loops as observed by crystallographic analyses. Of the tested ICA inhibitors, 55 displayed potent synergistic antibacterial activity with meropenem against engineered Escherichia coli strains and even intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL. The morphologic and internal structural changes of bacterial cells after treatment further demonstrated that 55 crossed the outer membrane and reversed the activity of meropenem. Moreover, 55 showed good pharmacokinetic and safety profile in vivo, which could be a potential candidate for combating VIM-mediated Gram-negative carbapenem resistance.

ATG7 INHIBITORS AND THE USES THEREOF

Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.

ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS

The present invention provides isoindolinone and pyrrolopyridinone derivatives, as well as their compositions and methods of use, that inhibit the activity of the serine/threonine kinase, Akt, and are useful in the treatment of diseases related to the act